Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE TAHERALY : revenue, balance sheet and financial ratios

SELARL PHARMACIE TAHERALY is a French company founded 15 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MARSEILLE (13001), this company of category PME shows in 2016 a revenue of 852 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE TAHERALY (SIREN 522954643)
Indicator 2022 2021 2020 2019 2016
Revenue N/C N/C N/C N/C 852 237 €
Net income 63 377 € 91 338 € 38 545 € 40 204 € 45 031 €
EBITDA N/C N/C N/C N/C 73 581 €
Net margin N/C N/C N/C N/C 5.3%

Revenue and income statement

In 2022, SELARL PHARMACIE TAHERALY generates positive net income of 63 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2022: 45 k€ -> 63 k€.

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

63 377 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 13%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 79%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

12.744%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

78.834%

Asset age ratio (2022) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

27.2%

Solvency indicators evolution
SELARL PHARMACIE TAHERALY

Sector positioning

Debt ratio
12.74 2022
2020
2021
2022
Q1: 24.5
Med: 74.73
Q3: 182.59
Excellent

In 2022, the debt ratio of SELARL PHARMACIE TAHERALY (12.74) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
78.83% 2022
2020
2021
2022
Q1: 28.53%
Med: 47.06%
Q3: 66.62%
Excellent

In 2022, the financial autonomy of SELARL PHARMACIE TAHERALY (78.8%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 132.95. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

132.954

Liquidity indicators evolution
SELARL PHARMACIE TAHERALY

Sector positioning

Liquidity ratio
132.95 2022
2020
2021
2022
Q1: 145.2
Med: 199.49
Q3: 275.01
Watch -22 pts over 3 years

In 2022, the liquidity ratio of SELARL PHARMACIE TAHERALY (132.95) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2022) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2022) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2022) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2022) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE TAHERALY

Positioning of SELARL PHARMACIE TAHERALY in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 215 transactions of similar company sales in 2022, the value of SELARL PHARMACIE TAHERALY is estimated at 745 726 € (range 501 276€ - 1 118 450€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2022
215 transactions
501k€ 745k€ 1118k€
745 726 € Range: 501 276€ - 1 118 450€
NAF 5 année 2022

Valuation method used

Net Income Multiple
63 377 € × 11.8x = 745 726 €
Range: 501 276€ - 1 118 451€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 215 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE TAHERALY with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE TAHERALY

What is the revenue of SELARL PHARMACIE TAHERALY ?

The revenue of SELARL PHARMACIE TAHERALY in 2016 is 852 k€.

Is SELARL PHARMACIE TAHERALY profitable?

Yes, SELARL PHARMACIE TAHERALY generated a net profit of 63 k€ in 2022.

Where is the headquarters of SELARL PHARMACIE TAHERALY ?

The headquarters of SELARL PHARMACIE TAHERALY is located in MARSEILLE (13001), in the department Bouches-du-Rhone.

Where to find the tax return of SELARL PHARMACIE TAHERALY ?

The tax return of SELARL PHARMACIE TAHERALY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE TAHERALY operate?

SELARL PHARMACIE TAHERALY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.